Johnson & Johnson's Phase 3 Study Evaluating CAPLYTA Met Its Primary And Key Secondary Endpoints
Benzinga Newsdesk 18 hours ago
BiotechGeneralNews
CAPLYTA improved manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3 and a safety and tolerability profile consistent with prior studiesTwo positive Phase 3 studies will support a
- CAPLYTA improved manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3 and a safety and tolerability profile consistent with prior studies
- Two positive Phase 3 studies will support a planned U.S. FDA submission of CAPLYTA for bipolar mania, reinforcing its potential to address both depressive and manic episodes of bipolar disorder